These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 19067473

  • 1. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D.
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
    Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D.
    Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.
    Grabowski B, Lee RD.
    Clin Drug Investig; 2012 May 01; 32(5):319-32. PubMed ID: 22455762
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W, Wu J, Atkinson SN.
    J Clin Pharmacol; 2009 Apr 01; 49(4):444-54. PubMed ID: 19318694
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
    Metz DC, Vakily M, Dixit T, Mulford D.
    Aliment Pharmacol Ther; 2009 May 01; 29(9):928-37. PubMed ID: 19298580
    [Abstract] [Full Text] [Related]

  • 13. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M, Kirby M, Robertson P, Hellriegel ET.
    Clin Pharmacokinet; 2008 May 01; 47(1):61-74. PubMed ID: 18076219
    [Abstract] [Full Text] [Related]

  • 14. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Peura D.
    Aliment Pharmacol Ther; 2009 Apr 01; 29(7):731-41. PubMed ID: 19183157
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
    Pan WJ, Goldwater DR, Zhang Y, Pilmer BL, Hunt RH.
    Aliment Pharmacol Ther; 2000 Mar 01; 14(3):345-52. PubMed ID: 10735929
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M, Bekersky I, Blum RA, Tolbert D.
    Pharmacotherapy; 2012 Apr 01; 32(4):340-53. PubMed ID: 22422635
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.